换一批Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer.
第一作者：
F,Loupakis
第一单位：
Unit of Medical Oncology, Department of Oncology, Transplants and New Technologies in Medicine, Azienda Ospedaliero-Universitaria Pisana and University of Pisa, Via Roma, 67, Pisa, 56126, Italy.
作者：
医学主题词
腺癌(Adenocarcinoma);成年人(Adult);老年人(Aged);抗体, 单克隆(Antibodies, Monoclonal);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);喜树碱(Camptothecin);结直肠肿瘤(Colorectal Neoplasms);用药计划表(Drug Administration Schedule);女(雌)性(Female);氟尿嘧啶(Fluorouracil);人类(Humans);醛氢叶酸(Leucovorin);男(雄)性(Male);中年人(Middle Aged);肿瘤辅助疗法(Neoadjuvant Therapy);肿瘤转移(Neoplasm Metastasis);新生血管化, 病理性(Neovascularization, Pathologic);有机铂化合物(Organoplatinum Compounds);遗传药理学(Pharmacogenetics);凝血酶敏感蛋白1(Thrombospondin 1);血管内皮生长因子A(Vascular Endothelial Growth Factor A);血管内皮生长因子受体2(Vascular Endothelial Growth Factor Receptor-2)
DOI
10.1038/bjc.2011.85
PMID
21407216
发布时间
2022-04-19
- 浏览24
British journal of cancer
1262-9页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
